| Identification | Back Directory | [Name]
SLC13A5-IN-1 | [CAS]
2227548-95-8 | [Synonyms]
SLC13A5-IN-1
N-[(4-chlorophenyl)methyl]-1-(3,5-dichlorobenzen esulfonyl)piperidine-4-carboxamide
4-Piperidinecarboxamide, N-[(4-chlorophenyl)methyl]-1-[(3,5-dichlorophenyl)sulfonyl]-
hSLC3A5,metabolic,SLC-13A5-IN-1,SLC13A5IN1,Inhibitor,Citrate,SLC13A5,cardiovascular,inhibit,disease,Sodium Channel,Uptake,Na channels,Na+ channels,SLC13A5 IN 1 | [Molecular Formula]
C19H19Cl3N2O3S | [MDL Number]
MFCD32671334 | [MOL File]
2227548-95-8.mol | [Molecular Weight]
461.79 |
| Chemical Properties | Back Directory | [density ]
1.436±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 7 mg/mL (15.16 mM);Ethanol: Insoluble | [form ]
Solid | [pka]
14.79±0.20(Predicted) | [color ]
White to off-white | [Water Solubility ]
Water: Insoluble |
| Hazard Information | Back Directory | [Uses]
SLC13A5-IN-1 is a selective sodium-citrate co-transporter (SLC13A5) inhibitor. SLC13A5-IN-1 completely blocks?the uptake of?14C-citrate with an IC50 value of 0.022 μM in HepG2 cells. SLC13A5-IN-1 has the potential for the treatment of metabolic and/or cardiovascular diseases. SLC13A5-IN-1 is extracted from patent WO2018104220A1, Compound I-5[1]. | [References]
[1] Joerg Kley, et al. Sulfonamides as inhibitors of the uptake of extracellular citrate. Patent WO2018104220A1 |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|